SGMT Sagimet Biosciences Inc

$SGMT All this is noise. We aren't playing for percentages, we are playing for multiples. We've seen the downside, now let's see the upside.

$SGMT Technicals right now are horrible. However, the fundamentals are this: 70M shares outstanding is 560M Market cap with 360M in cash. This equates to an EV of just 200M. The Chinese milestones/royalties are worth 150M+ by themselves. Some very astute investors just paid 10/share for 11M shares just 2 weeks ago. This an extremely cheap option on the US and European acne market.

Oppenheimer⬆️ $SGMT's PT to $38 and reiterated Outperform after SGMT/Ascletis presented full 52-week Ph3 OLE data for denifanstat (deni) in moderate-to-severe acne at EADV and hosted a KOL event. $ASCLF $GALDY DRMA MDGL IVA LLY NVO ALGS VKTX Oppenheimer said -- We view the results as incrementally encouraging, particularly around continued efficacy improvement with longer treatment and durable safety. IGA success increased from 33% at Week 12 to ~58% at the end of the OLE, while total/inflammatory lesion reductions similarly improved from 57%/64% to 73%/78%, respectively. Importantly, longer exposure did not appear to compromise tolerability, with no AE-related permanent discontinuations or drug-related SAEs. We believe these findings further strengthen deni's differentiated profile and support the potential for longer treatment duration in real-world practice. We update our model and increase our PT to $38 (vs. prior $33), driven by our assumption of a longer treatment duration.

$SGMT the macro environment and immaterial moves make andrea newkirk look correct even if completely unrelated to her very under researched thesis that almost certainly served as a kind of hit piece. the company has cash, the company has a product, and chinese approval is on the way as a somewhat meaningful catalyst with near certainty (that’s the NDA approval). pretty sure that was priced in before at 11 dollars. at 7 dollars? don’t think it’s priced in anymore.

$SGMT My 2cents on this offering and data. The data is strong as Happel had indicated but a little shy of accutane results. They are about 80% of accutane but with a much stronger safety profile. Only AEs are dry eye and skin. That means deni can be taken safely for a much longer period of time. The 52wk only cohort showed better results than the 12wk Placebo/40 wk deni cohort suggesting that there may be additional benefits beyond 52 wks. I'm a little disappointed by the offering this early but it was clearly motivated by reverse inquiry. This offering is priced 66.7% above the last offering and was led by a lot of the previous investors from the last offerring. They are averaging up not down. For clinical stage bios, more cash is always better than less cash but I think they should have waited till after the EADV numbers. Also, we now know the motivation beyond the BS sell rating. They most likely wanted to be involved in the offering and were rebuffed.

$SGMT they wasted no time on that offering lol Just peanuts in the grand scheme of things. Great data and f*ck Goldman sacks lol

$SGMT The guys at Goldman Sachs looking at DEI hire Andrea Newkirk's latest downgrade at SGMT be like...

First patient dosed and $SGMT actually has a clock now AURORA Phase 3 is live for denifanstat in moderate to severe acne once daily pill, novel mechanism, nothing like it approved in over 40 years if it gets there topline sits in the second half of 2027, about 10 million US patients in that bucket closed Wednesday at 9.99, up 2.6 percent, and up about 25 percent in five sessions imo

$SGMT it’s obvious now that we have ourselves a big whale on the line that has decided to take position with a few million shares

$SGMT Andrea got scolded yesterday and her boss said you better do a better job if you plan on staying here.

$SGMT Goldman’s SGMT history looks suspicious. When Goldman helped underwrite SGMT, it carried bullish targets into the $30s. Afterward: $23.X → $6. SGMT’s 2026 $175M raise went to other banks. Now Goldman returns with a Street-low $7.X Sell based on surprisingly thin reasoning: endpoints despite comparable China data at p<0.0001, FDA-requested adolescent enrollment framed as risk, and “adherence” concerns over one daily pill. IOVA had a similarly wild Goldman cycle: underwriter → $1.X–2 Sell → now $15 Buy. Whatever the explanation, this pattern and research quality deserve scrutiny.

$SGMT and just like that this mudhaphukka is above $9. With biotech doing so shitty and this just post offering. 💪 I am so proud of you 👏 saggy

$SGMT 🏥 Sagimet Biosciences Inc. announces first patient dosed in its AURORA Phase 3 U.S. clinical trial of denifanstat for moderate to severe acne, designed to enroll approximately 800 U.S. patients to advance its U.S. registrational program. Selected from hundreds of headlines

$SGMT guys I’m first in line for the rug and tugs! I bought the hell outta the dip! I deserve to get paid

$SGMT What's going on here? Shorts covering? Love to see this action these last two days after the ass blasting we all over the last couple of weeks.

$SGMT I guess this is the new norm now-we have the morning dump to only climb back up the last 30 minutes of the day back to some equilibrium.

$SGMT I didn’t pick sgmt because they were supposed to be BIC from an efficacy perspective. I picked it because it was BIC for overall long term sustainability in a ginormous market. Nothing changed. Everything validated Denifanstat is not meant to completely replace Accutane for the most extreme, recalcitrant nodulocystic cases. Instead, it positions as a first-line oral maintenance therapy for moderate-to-severe acne, appealing to patients and dermatologists who refuse or cannot tolerate Accutane's side effect profile and iPLEDGE compliance burden.

$SGMT $9.95 bid Holding long position at $4.56 https://stocktwits.com/G101SPM/message/589116166 UPDATE: Sagimet Biosciences (SGMT) priced an offering of about 8.8 million shares of series A common stock at $10 per share for gross proceeds of approximately $115 million, the company said Wednesday. The company also priced pre-funded warrants to purchase approximately 2.8 million shares at $9.9999 per warrant. Sagimet expects the offering to generate about $115 million in fross proceeds. Commodore Capital leads the offering, with participation from RA Capital Management, Spruce Street Capital, BVF Partners, Aberdeen Investments, Columbia Threadneedle Investments, Affinity Asset Advisors and Woodline Partners. Net proceeds from the offering, together with existing cash and cash equivalents, will be used to fund a phase 3 trial of denifanstat in acne and pre-launch activities, to advance TVB-3567 through phase 2 topline results, and to advance its topical FASN inhibitor program toward an investigational new drug submission.

$SGMT Sagimet Biosciences reports results from Phase 3 ASC40-304 OLE clinical trial Sagimet Biosciences announced positive 52-week results from the Phase 3 ASC40-304 OLE clinical trial of denifanstat in patients with moderate to severe acne vulgaris, conducted by license partner Ascletis BioScience in China. The results were presented at the European Academy of Dermatology and Venereology Congress, or EADV, in Vienna by Ascletis. Denifanstat is a once-daily oral small molecule fatty acid synthase, or FASN, inhibitor being developed by Ascletis as ASC40 in China where it holds an exclusive license to denifanstat, and by Sagimet in the rest of the world. The Phase 3 OLE clinical trial, ASC40-304, evaluated the long-term safety of denifanstat in patients with moderate to severe acne vulgaris who were previously enrolled in the 12-week randomized, double-blind, placebo-controlled Phase 3 ASC40-303 clinical trial, conducted in China by Ascletis. 240 patients rolled over into the OLE trial, for a total trial duration of up to 52 weeks. Denifanstat was generally well-tolerated in the OLE with patients receiving up to 52 weeks of exposure, with no permanent discontinuations of study drug due to adverse events and no drug-related serious adverse events among patients treated with denifanstat. Only two categories of treatment-related adverse events had an incidence of more than 5% over the 52-week period: dry skin in 7.1% and dry eye in 5.9%.

$SGMT Well I'll be damned, Goldman Sachs was right. I know when I've lost and tip my hat to the woman I bad mouthed when she called out 7 bucks as the new PT. This stock is steaming pile of dogshit.